To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme
Brain tumours kill more people aged under 40 than any other cancer, yet there have been no new treatments for more than a decade. What’s more, there are still none in the pipeline.
Connecting with patients has become a central plank in the pharma marketing playbook, but should companies be looking for a wider view when looking for insights to inform their branding?